Literature DB >> 848929

Pharmacokinetics of cefamandole in patients with renal failure.

B R Meyers, S Z Hirschman.   

Abstract

The pharmacokinetics of cefamandole were studied in four patients with stable renal failure, two patients undergoing peritoneal dialysis, and four patients undergoing hemodialysis. Peak concentrations of cefamandole in serum were achieved 1 to 2 h after intramuscular injection in the patients with stable renal impairment, and the concentrations declined slowly, with half-life values of 12.3 to 18 h. Cefamandole was removed only very slowly by peritoneal dialysis. Hemodialysis was more efficient in removing cefamandole, with serum half-life values ranging from 3.8 to 7.9 h. The mean apparent volume of distribution of cefamandole in these 10 patients was 21.92 liters, or 31% of the body weight.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 848929      PMCID: PMC351962          DOI: 10.1128/AAC.11.2.248

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Pharmacological studies with cefamandole in human volunteers.

Authors:  B R Meyers; B Ribner; S Yancovitz; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

3.  Blood and urine levels of cephalexin in patients with impaired renal function.

Authors:  R H Butcher; J K Dawborn; G Pattison
Journal:  Med J Aust       Date:  1972-12-02       Impact factor: 7.738

4.  Cephalothin and cephaloridine: comparative pharmacodynamics in chronic uremia.

Authors:  R L Perkins; E J Smith; S Saslaw
Journal:  Am J Med Sci       Date:  1969-02       Impact factor: 2.378

5.  Cephalexin in patients with renal disease.

Authors:  J A Linquist; J Y Siddiqui; I M Smith
Journal:  N Engl J Med       Date:  1970-10-01       Impact factor: 91.245

6.  Cefamandole, a cephalosporin antibiotic with an unusually wide spectrum of activity.

Authors:  H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1974-08       Impact factor: 5.191

7.  Effect of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium.

Authors:  R V McCloskey; E E Terry; A W McCracken; M J Sweeney; M F Forland
Journal:  Antimicrob Agents Chemother       Date:  1972-02       Impact factor: 5.191

8.  Excretion of cephaloridine and cephalothin in patients with renal impairment.

Authors:  C M Kunin; N Atuk
Journal:  N Engl J Med       Date:  1966-03-24       Impact factor: 91.245

9.  Cefamandole: antimicrobial activity in vitro of a new cephalosporin.

Authors:  B R Meyers; B Leng; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1975-12       Impact factor: 5.191

10.  Antibacterial activity of cefamandole, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cephalexin.

Authors:  S Eykyn; C Jenkins; A King; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1973-06       Impact factor: 5.191

  10 in total
  4 in total

Review 1.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

3.  Pharmacokinetics of cefamandole in patients with renal impairment.

Authors:  A W Czerwinski; J A Pederson
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

4.  Disposition kinetics of cefamandole during continuous ambulatory peritoneal dialysis.

Authors:  M Bliss; M Mayersohn; T Arnold; J Logan; U F Michael; W Jones
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.